Abstract
The Pharmacokinetics, Optimal Dose and Therapeutic Monitoring of Vancomycin in Severe Burn Patients
Highlights
Vancomycin, a potential nephrotoxic antibiotic, is commonly used in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection or sepsis
A daily dose of at least 5000 mg is suggested in severe burn patients with normal renal function (CLCr>90 mL/min)
Nine young adult burn patients were included in this study, and each individual was matched with a non-burn critical ill patient
Summary
Vancomycin, a potential nephrotoxic antibiotic, is commonly used in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection or sepsis. The antibiotic is excreted by kidney and 55% of it is bound to albumin [1]. The pharmacokinetics (PK) is significantly altered in severe burn patients [2,3]. As Ctrough significantly correlates with the AUC24 h, a Ctrough level of 15–20 mg/L is recommended to achieve an AUC24h/ MIC of 400 if the MIC is 1 mg/L. Its use as reference for dosage adjustment in severe burns patients has been questioned as the correlation of Ctrough with AUC24h remains debatable in this special group [9,10]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
